Metformin Vitabalans
Biguanide Antidiabetic for Type 2 Diabetes Mellitus
Quick Facts About Metformin Vitabalans
Key Takeaways About Metformin Vitabalans
- First-line diabetes treatment: Metformin is recommended as the initial pharmacological therapy for type 2 diabetes by the ADA, EASD, and WHO due to its proven efficacy, cardiovascular benefits, and low cost
- Does not cause hypoglycaemia alone: Unlike sulfonylureas or insulin, metformin does not stimulate insulin secretion and therefore does not cause low blood sugar when used as monotherapy
- GI side effects are common but manageable: Nausea, diarrhoea, and abdominal discomfort affect more than 10% of patients but typically improve with gradual dose titration and taking the medicine with food
- Kidney function must be monitored: Metformin is cleared by the kidneys; dose reduction is needed when eGFR falls below 45 mL/min and the drug must be stopped if eGFR drops below 30 mL/min
- Stop before contrast procedures: Metformin must be temporarily discontinued before receiving iodinated contrast media for imaging studies due to the risk of acute kidney injury and lactic acidosis
What Is Metformin Vitabalans and What Is It Used For?
Metformin Vitabalans is a prescription medicine containing metformin hydrochloride, the most widely prescribed oral antidiabetic drug in the world. It belongs to the biguanide class of medications and has been used in clinical practice for over 60 years. Its long track record of safety and efficacy, combined with demonstrated cardiovascular benefits and a very low cost, has made it the universally recommended first-choice medication for type 2 diabetes mellitus.
Type 2 diabetes is a chronic metabolic disorder characterised by insulin resistance and progressive beta-cell dysfunction, leading to persistently elevated blood glucose levels. If left untreated or poorly controlled, high blood sugar damages blood vessels and nerves throughout the body, increasing the risk of heart disease, stroke, kidney failure, blindness, and lower limb amputation. Metformin addresses the core pathophysiology of type 2 diabetes through three complementary mechanisms of action.
First, metformin reduces hepatic glucose output by activating AMP-activated protein kinase (AMPK), a key cellular energy sensor. This suppresses gluconeogenesis – the process by which the liver manufactures new glucose – which is abnormally elevated in type 2 diabetes and is a major contributor to fasting hyperglycaemia. Second, metformin increases insulin sensitivity in peripheral tissues, primarily skeletal muscle, allowing cells to take up and utilise glucose more effectively. Third, it delays the absorption of glucose from the gastrointestinal tract, helping to blunt post-meal blood sugar spikes.
The landmark UK Prospective Diabetes Study (UKPDS) demonstrated that metformin reduced the risk of diabetes-related death by 42% and all-cause mortality by 36% in overweight patients with type 2 diabetes, compared with diet alone. This cardiovascular benefit is unique among antidiabetic drugs and is a key reason why all major international guidelines – including those from the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and the World Health Organization (WHO) – recommend metformin as first-line pharmacological therapy.
Metformin Vitabalans can be used as monotherapy when diet and exercise alone are insufficient to achieve adequate glycaemic control, or in combination with other oral antidiabetic medicines (such as sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, or thiazolidinediones) or with insulin. The choice of combination therapy depends on individual patient factors including HbA1c level, body weight, kidney function, cardiovascular risk, and patient preferences.
Indications
- Type 2 diabetes mellitus in adults: As monotherapy or in combination with other antidiabetic agents, when diet and exercise alone do not achieve adequate glycaemic control
- Type 2 diabetes mellitus in children aged 10 years and over and adolescents: As monotherapy or in combination with insulin
- Prevention of type 2 diabetes: While not a licensed indication in all countries, metformin is recommended by the ADA for diabetes prevention in high-risk individuals with prediabetes, particularly those with a BMI of 35 or above, those under 60 years of age, or women with a history of gestational diabetes
What Should You Know Before Taking Metformin Vitabalans?
Before starting Metformin Vitabalans, your doctor will assess your overall health to ensure it is safe for you. Several medical conditions can increase the risk of serious side effects, particularly lactic acidosis. It is essential to inform your doctor about all your medical conditions, all other medications you are taking (including over-the-counter products and supplements), and whether you consume alcohol regularly.
Contraindications
- Severe renal impairment (eGFR below 30 mL/min) – metformin is cleared by the kidneys and may accumulate to dangerous levels
- Diabetic ketoacidosis or diabetic precoma – insulin is the appropriate treatment for these conditions
- Any condition that may cause tissue hypoxia, including decompensated heart failure, respiratory failure, recent myocardial infarction, or circulatory shock
- Severe hepatic insufficiency – the liver plays a role in lactic acid clearance
- Acute alcohol intoxication or alcoholism – alcohol impairs hepatic lactate metabolism
- Hypersensitivity to metformin hydrochloride or any of the excipients
Warnings and Precautions
Lactic acidosis is a very rare (approximately 3–10 cases per 100,000 patient-years) but potentially fatal metabolic emergency that can occur with metformin use. It is characterised by acidotic dyspnoea (laboured breathing), abdominal pain, muscle cramps, hypothermia, and subsequent coma. The risk is almost exclusively associated with identifiable predisposing factors such as significant renal impairment, dehydration, sepsis, acute heart failure, hepatic disease, or excessive alcohol consumption. Patients should be educated about the warning signs and instructed to stop metformin and seek immediate medical attention if they develop these symptoms.
Kidney function monitoring is essential. Renal function (estimated glomerular filtration rate, eGFR) should be assessed before initiating metformin and at least annually thereafter. In patients with additional risk factors for renal decline (such as elderly patients, those taking nephrotoxic medications, or those with borderline eGFR), monitoring should occur every 3 to 6 months. Current guidelines recommend:
- eGFR 45–59 mL/min: Consider dose reduction; monitor kidney function every 3–6 months
- eGFR 30–44 mL/min: Maximum dose 1000 mg/day; do not initiate metformin in new patients
- eGFR below 30 mL/min: Metformin must be discontinued
Iodinated contrast media: Metformin must be discontinued at the time of, or prior to, imaging procedures involving intravascular administration of iodinated contrast agents. Contrast media can cause acute deterioration of kidney function, potentially leading to metformin accumulation and lactic acidosis. Metformin should not be restarted until at least 48 hours after the procedure and only after renal function has been re-evaluated and found to be stable.
Surgery: Metformin should be discontinued at the time of surgery under general, spinal, or epidural anaesthesia. It may be restarted no earlier than 48 hours after the procedure and only after oral intake has resumed and renal function has been confirmed as stable.
Long-term metformin use has been associated with decreased vitamin B12 absorption, potentially leading to clinically significant vitamin B12 deficiency in 5–10% of patients. Symptoms may include peripheral neuropathy, which can be mistaken for diabetic neuropathy. Periodic monitoring of vitamin B12 levels is advisable, especially in patients with anaemia or peripheral neuropathy. Supplementation should be considered if levels are low.
Pregnancy and Breastfeeding
Pregnancy: Uncontrolled diabetes during pregnancy carries significant risks for both the mother and the developing baby, including congenital malformations, macrosomia, and perinatal complications. When drug treatment for type 2 diabetes is needed during pregnancy, insulin is the preferred therapy because it does not cross the placenta. However, limited clinical data on metformin use in pregnancy have not shown an increased risk of congenital abnormalities. Some guidelines (notably NICE in the UK) consider metformin as an option during pregnancy, particularly for gestational diabetes, but this decision should always be made in consultation with a specialist.
Breastfeeding: Metformin is excreted in human breast milk in small amounts. The level of metformin in breast milk is very low (typically less than 1% of the maternal dose), and no adverse effects have been observed in breastfed infants. Most guidelines consider metformin compatible with breastfeeding, but you should discuss this with your doctor.
How Does Metformin Vitabalans Interact with Other Drugs?
Drug interactions with metformin are clinically important because they can either increase the risk of adverse effects (particularly lactic acidosis) or alter blood glucose control. Unlike many other medications, metformin is not metabolised by the liver and does not interact with cytochrome P450 enzymes. Instead, it is excreted unchanged by the kidneys via tubular secretion, so interactions primarily involve drugs that affect renal function or compete for the same renal transport pathways.
Major Interactions
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| Iodinated contrast media | Contrast can cause acute kidney injury, leading to metformin accumulation and lactic acidosis | Stop metformin before the procedure; restart only after 48 hours and confirmed stable kidney function |
| Alcohol | Alcohol impairs hepatic lactate metabolism, increasing the risk of lactic acidosis; also increases hypoglycaemia risk | Avoid excessive alcohol intake; be particularly cautious with binge drinking or chronic heavy use |
| Cimetidine | Competes for renal tubular secretion, increasing metformin plasma levels by up to 60% | Consider dose adjustment or use alternative H2 blocker (ranitidine, famotidine) |
| Dolutegravir | Inhibits OCT2 and MATE1 transporters, significantly increasing metformin exposure | Consider reducing metformin dose when starting or stopping dolutegravir; monitor blood glucose |
| Vandetanib | Inhibits renal OCT2 transporter, increasing metformin plasma concentrations | Monitor kidney function and blood glucose closely; consider dose adjustment |
Other Important Interactions
| Drug / Class | Effect on Blood Sugar | Clinical Significance |
|---|---|---|
| Corticosteroids (prednisolone, dexamethasone) | Increase blood glucose – may reduce metformin efficacy | Monitor blood glucose more frequently; may need to increase metformin dose or add another antidiabetic |
| Beta-2 agonists (salbutamol, terbutaline) | Increase blood glucose through glycogenolysis stimulation | Monitor blood glucose during treatment; usually clinically significant only with systemic use |
| ACE inhibitors (enalapril, ramipril) | May lower blood glucose and enhance metformin effect | Monitor blood glucose; may need to reduce metformin dose in some patients |
| Diuretics (furosemide, hydrochlorothiazide) | Thiazides may increase blood glucose; loop diuretics may impair renal function | Monitor kidney function and blood glucose; ensure adequate hydration |
| Insulin / Sulfonylureas | Additive blood glucose lowering – increased hypoglycaemia risk | May need to reduce insulin or sulfonylurea dose when combined with metformin |
What Is the Correct Dosage of Metformin Vitabalans?
The dosage of Metformin Vitabalans must be individualised based on blood glucose measurements, HbA1c levels, tolerability, and kidney function. A key principle of metformin prescribing is gradual dose escalation – starting with a low dose and increasing slowly to minimise gastrointestinal side effects. Taking metformin with or immediately after meals also significantly reduces nausea and diarrhoea.
Adults
Adult Dosing Schedule
- Starting dose: 500 mg once daily or 500 mg twice daily, taken with meals
- Dose titration: Increase by 500 mg every 1–2 weeks based on blood glucose response and tolerability
- Usual maintenance dose: 1500–2000 mg per day in 2–3 divided doses
- Maximum dose: 3000 mg per day (some guidelines recommend a maximum of 2550 mg/day)
- Administration: Always take during or after meals; divide total daily dose into 2–3 doses
Clinical studies suggest that the majority of the glucose-lowering effect of metformin is achieved at a dose of approximately 1500–2000 mg per day. Increasing beyond 2000 mg/day provides only modest additional HbA1c reduction (approximately 0.1–0.2%) but substantially increases the frequency and severity of gastrointestinal side effects. For this reason, many clinicians consider 2000 mg per day to be the practical maximum dose.
Children (aged 10 years and over)
Paediatric Dosing Schedule
- Starting dose: 500 mg once daily, taken with the evening meal
- Dose titration: Increase by 500 mg every 1–2 weeks based on blood glucose and tolerability
- Maximum dose: 2000 mg per day in 2–3 divided doses
Metformin is approved for use in children aged 10 years and older with type 2 diabetes, either as monotherapy or combined with insulin. Clinical trial data in paediatric populations are more limited than in adults, but available evidence supports similar efficacy and safety profiles. Close monitoring by a paediatric endocrinologist is recommended.
Elderly Patients
Elderly patients are at increased risk of metformin-associated adverse effects due to the natural decline in kidney function that occurs with ageing. Dosing should be based on careful assessment of renal function (eGFR). Kidney function should be monitored at least every 3–6 months in patients over 65 years of age. The dose should be the minimum effective dose, and the maximum daily dose should generally not exceed 2000 mg in elderly patients.
Patients with Reduced Kidney Function
| eGFR (mL/min) | Maximum Daily Dose | Monitoring |
|---|---|---|
| 60 or above | Up to 3000 mg (full dose) | At least annually |
| 45–59 | Up to 2000 mg | Every 3–6 months |
| 30–44 | Up to 1000 mg (do not start in new patients) | Every 3 months |
| Below 30 | Contraindicated – stop metformin | N/A |
Missed Dose
If you miss a dose of Metformin Vitabalans, take it as soon as you remember, provided it is close to the time of a meal. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten dose. Missing a single dose of metformin is unlikely to cause a significant change in your blood sugar control.
Overdose
Hypoglycaemia has not been observed with metformin doses of up to 85 g (over 40 times the maximum recommended daily dose), although lactic acidosis has occurred in such circumstances. Massive metformin overdose or co-existing risk factors for lactic acidosis may lead to a life-threatening metabolic emergency. Symptoms of lactic acidosis include severe nausea, vomiting, diarrhoea, rapid or deep breathing, abdominal pain, muscle cramps, lethargy, and hypothermia. Treatment is supportive: metformin is dialysable, and haemodialysis is the treatment of choice in severe cases. If you suspect an overdose, call your local emergency services immediately.
What Are the Side Effects of Metformin Vitabalans?
Like all medicines, Metformin Vitabalans can cause side effects, although not everybody gets them. The vast majority of metformin side effects are gastrointestinal and dose-related, meaning they are more likely to occur at higher doses and at the start of treatment. They can be substantially minimised by starting with a low dose, increasing gradually, and always taking metformin with food.
If you experience any side effects that concern you, or if side effects are persistent or severe, consult your doctor or pharmacist. Some side effects require immediate medical attention – particularly signs of lactic acidosis (see below).
Very Common (affects more than 1 in 10 people)
- Nausea
- Vomiting
- Diarrhoea
- Abdominal pain and cramping
- Loss of appetite (anorexia)
Common (affects 1 in 10 to 1 in 100 people)
- Metallic taste (dysgeusia)
- Flatulence
- Abdominal distension
Uncommon (affects 1 in 100 to 1 in 1,000 people)
- Skin rash, itching (pruritus), or hives (urticaria)
- Abnormal liver function tests
Rare and Very Rare (affects fewer than 1 in 1,000 people)
- Lactic acidosis (very rare, potentially fatal – see warning above)
- Vitamin B12 deficiency with prolonged use (decreased absorption)
- Hepatitis (liver inflammation)
- Erythema (skin redness)
Stop taking Metformin Vitabalans and contact emergency services immediately if you experience signs of lactic acidosis: rapid or deep breathing, persistent nausea or vomiting, severe stomach pain, muscle cramps, unusual tiredness or weakness, feeling very cold, or feeling faint or dizzy. Lactic acidosis is a medical emergency with a high mortality rate if not treated promptly.
Gastrointestinal side effects are by far the most frequently reported adverse reactions to metformin. They occur in approximately 20–30% of patients, most commonly during the first few weeks of treatment. In most cases, they are mild to moderate and self-limiting. Evidence-based strategies to minimise GI side effects include:
- Starting with the lowest available dose (500 mg once daily) and increasing gradually over several weeks
- Always taking metformin during or immediately after a meal
- Dividing the total daily dose into 2–3 separate doses rather than taking it all at once
- Switching to an extended-release (prolonged-release) formulation if standard-release tablets are not tolerated
Vitamin B12 malabsorption is an increasingly recognised long-term consequence of metformin therapy. A meta-analysis published in the BMJ found that metformin use was associated with a 26% reduction in serum vitamin B12 levels compared with placebo. Clinically significant deficiency (defined as serum B12 below 150 pmol/L) has been reported in 5–10% of long-term users. Since vitamin B12 deficiency can cause irreversible neurological damage, including peripheral neuropathy that may be difficult to distinguish from diabetic neuropathy, regular screening and appropriate supplementation are recommended.
How Should You Store Metformin Vitabalans?
Proper storage of Metformin Vitabalans is important to ensure the medicine remains effective and safe throughout its shelf life. Film-coated tablets should be stored at room temperature, below 25°C, in the original blister packaging or container to protect from moisture and light. Do not store in the bathroom or near a heat source, as humidity and high temperatures can degrade the active ingredient.
Keep this medicine out of the sight and reach of children. The packaging is designed to be child-resistant, but additional precautions should be taken, such as storing medicines in a locked cabinet or a high shelf.
Do not use Metformin Vitabalans after the expiry date stated on the packaging (after “EXP”). The expiry date refers to the last day of that month. If you notice any change in the appearance of the tablets (discolouration, crumbling, unusual odour), do not take them and consult your pharmacist.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help to protect the environment. In many countries, pharmacies and community collection points offer free medicine disposal services.
What Does Metformin Vitabalans Contain?
Understanding the composition of your medicine helps you identify whether you may be allergic or intolerant to any of the ingredients. If you have known allergies to any pharmaceutical excipients, check the full ingredient list below and discuss with your pharmacist or doctor.
Active Substance
Each film-coated tablet contains 500 mg metformin hydrochloride, corresponding to approximately 390 mg of metformin base. Metformin hydrochloride is a white, crystalline powder that is freely soluble in water. It belongs to the biguanide class of antidiabetic agents and is chemically described as 1,1-dimethylbiguanide hydrochloride.
Excipients
Tablet core: Povidone (K 30), magnesium stearate.
Film coating: Hypromellose, macrogol 400, macrogol 8000.
Appearance
Metformin Vitabalans 500 mg film-coated tablets are white to off-white, round, biconvex tablets. They may bear a score line to facilitate breaking the tablet in half if needed for dose adjustment, although this varies by manufacturer batch.
Frequently Asked Questions About Metformin Vitabalans
Metformin Vitabalans is used to treat type 2 diabetes mellitus, particularly in overweight patients, when diet and exercise alone do not provide adequate blood sugar control. It can be used as monotherapy or in combination with other oral antidiabetic medicines or insulin. Metformin is recommended as first-line pharmacological therapy for type 2 diabetes by all major international guidelines, including the ADA, EASD, and WHO.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, abdominal pain, and loss of appetite. These affect more than 1 in 10 patients and are most frequent during the first weeks of treatment. Taking metformin with or after meals and increasing the dose gradually can significantly reduce these effects. A metallic taste in the mouth is also common. Most gastrointestinal side effects improve on their own within a few weeks.
When used alone (monotherapy), metformin does not cause hypoglycaemia because it does not stimulate insulin secretion from the pancreas. However, if metformin is combined with insulin or sulfonylureas (such as glipizide or gliclazide), the risk of hypoglycaemia increases. If you experience symptoms such as sweating, trembling, hunger, or confusion while taking combination therapy, consume a fast-acting sugar source immediately and contact your doctor.
Lactic acidosis is a very rare but serious metabolic condition where lactic acid builds up in the blood faster than it can be removed. It occurs in approximately 3–10 cases per 100,000 patient-years of metformin use. Risk factors include severe kidney impairment, liver disease, excessive alcohol intake, dehydration, and conditions causing tissue hypoxia (such as severe heart failure). Symptoms include rapid breathing, muscle pain, stomach pain, and feeling cold. Seek emergency medical attention immediately if you experience these symptoms.
Yes, metformin should be discontinued at the time of, or prior to, procedures involving iodinated contrast media. The contrast dye can temporarily affect kidney function, which may lead to metformin accumulating in the body and increasing the risk of lactic acidosis. Metformin can usually be restarted 48 hours after the procedure, once kidney function has been confirmed as stable by a blood test (serum creatinine/eGFR). Your radiology or medical team will typically advise you about this.
Alcohol should be consumed with caution while taking metformin. Excessive alcohol intake (both acute binge drinking and chronic heavy use) increases the risk of lactic acidosis because alcohol impairs the liver’s ability to clear lactic acid. Alcohol can also increase the risk of hypoglycaemia, especially if you are also taking insulin or sulfonylureas. Moderate, occasional alcohol consumption with food is generally considered acceptable, but you should discuss your individual risk with your doctor.
References
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 1998;352(9131):854-865. doi:10.1016/S0140-6736(98)07037-8
- American Diabetes Association. Standards of Medical Care in Diabetes – 2024. Diabetes Care. 2024;47(Supplement 1). doi:10.2337/dc24-SINT
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycaemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. doi:10.2337/dci22-0034
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG28). Updated 2022. Available at: nice.org.uk/guidance/ng28
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List. 2023. Metformin included as essential medicine for diabetes mellitus.
- European Medicines Agency (EMA). Metformin-containing medicinal products – Article 31 referral: use in patients with moderately reduced kidney function. 2016. EMA/867221/2016.
- Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. Journal of Clinical Endocrinology & Metabolism. 2016;101(4):1754-1761. doi:10.1210/jc.2015-3754
- British National Formulary (BNF). Metformin hydrochloride. Updated 2024. Available at: bnf.nice.org.uk
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Endocrinology, Clinical Pharmacology, and Internal Medicine
Medical Review
iMedic Medical Review Board – Independent panel reviewing content according to ADA, EASD, and WHO guidelines
Evidence Standard: All medical claims in this article are based on Level 1A evidence (systematic reviews and meta-analyses of randomised controlled trials) following the GRADE evidence framework. Sources include the UKPDS, ADA/EASD Consensus Report 2022, WHO Essential Medicines List, NICE NG28, and BNF monographs.